[68Ga]Ga-NNS309
- Generic Name
- [68Ga]Ga-NNS309
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1
Recruiting
- Conditions
- Colorectal CancerPancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT06562192
- Locations
- 🇨ðŸ‡
Novartis Investigative Site, Geneve 14, Switzerland
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath